RESUMEN
Brain tumors and paraneoplastic syndromes can cause various neuropsychiatric symptoms. Rarely, psychiatric symptoms may be the initial presentation of the underlying neurologic lesion. Brain imaging studies are crucial in the diagnosis of brain tumors. Paraneoplastic syndromes are mostly immune-mediated, and antineuronal antibodies may be detected in the blood or cerebrospinal fluid. Clinical suspicion is very important in assisting the diagnostic workup. Treatment of the psychiatric symptoms depends on the nature of the symptoms. Selection of the psychotropic agent has to be done carefully to minimize complications such as seizures and delirium secondary to anticholinergic toxicity. With advances in targeted therapies, immunology, and genetics, the future appears more promising.
Asunto(s)
Autoanticuerpos/sangre , Neoplasias Encefálicas/sangre , Neoplasias Encefálicas/tratamiento farmacológico , Síndromes Paraneoplásicos del Sistema Nervioso/sangre , Síndromes Paraneoplásicos del Sistema Nervioso/tratamiento farmacológico , Humanos , Factores Inmunológicos/uso terapéutico , Encefalitis Límbica/sangre , Encefalitis Límbica/tratamiento farmacológico , Encefalitis Límbica/psicología , Síndromes Paraneoplásicos del Sistema Nervioso/psicología , Psicofarmacología , Psicotrópicos/uso terapéuticoAsunto(s)
Enfermedades Autoinmunes del Sistema Nervioso/diagnóstico , Depresión/diagnóstico , Encefalitis/diagnóstico , Síndromes Paraneoplásicos del Sistema Nervioso/diagnóstico , Trastornos Parkinsonianos/diagnóstico , Pérdida de Peso , Anciano , Autoanticuerpos/inmunología , Enfermedades Autoinmunes del Sistema Nervioso/psicología , Enfermedades Autoinmunes del Sistema Nervioso/terapia , Depresión/terapia , Diagnóstico Diferencial , Encefalitis/psicología , Encefalitis/terapia , Resultado Fatal , Humanos , Péptidos y Proteínas de Señalización Intracelular , Leucemia/complicaciones , Leucemia/inmunología , Masculino , Síndromes Paraneoplásicos del Sistema Nervioso/psicología , Síndromes Paraneoplásicos del Sistema Nervioso/terapia , Trastornos Parkinsonianos/terapia , Proteínas/inmunologíaRESUMEN
BACKGROUND: Patients with intracellular onconeural antibodies may present with neuro-psychiatric syndromes. We aimed to evaluate the evidence for an association between well-characterized onconeural antibodies and psychiatric symptoms in patients with and without paraneoplastic central nervous system syndromes. METHODS: Eligible studies were selected from 1980 until February 2017 according to standardized review criteria and evaluated using Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2). We included studies describing the psychiatric symptomatology of onconeural antibody positive patients and the prevalence of onconeural antibodies in patients with psychiatric disorders. RESULTS: Twenty-seven studies met the inclusion criteria. Six studies reported on the prevalence of well-characterized onconeural antibodies in patients with different psychiatric disorders, ranging from 0% to 4.9%. Antibody prevalence in controls was available from three studies, ranging from 0% to 2.8%. Data heterogeneity precluded a meta-analysis. Two cerebrospinal fluid studies found well-characterized onconeural antibodies in 3.5% and 0% of patients with psychotic and depressive syndromes, respectively. CONCLUSIONS: The available evidence suggests that the prevalence of well-characterized onconeural antibodies in patients with psychiatric disorders is generally low. However, the question whether onconeural antibodies are important in select patients with a purely psychiatric phenotype needs to be addressed by appropriately designed studies in the future.
Asunto(s)
Anticuerpos Antineoplásicos/inmunología , Trastornos Mentales/psicología , Síndromes Paraneoplásicos del Sistema Nervioso/psicología , Humanos , Trastornos Mentales/líquido cefalorraquídeo , Trastornos Mentales/inmunología , Síndromes Paraneoplásicos del Sistema Nervioso/líquido cefalorraquídeo , Síndromes Paraneoplásicos del Sistema Nervioso/inmunologíaRESUMEN
Paraneoplastic neurological disorders associated with onconeural antibodies often appear with neuropsychiatric symptoms. To study the prevalence of onconeural antibodies in patients admitted to acute psychiatric inpatient care, the serum of 585 such patients was tested for antibodies targeting MOG, GLRA1B, DPPX, GRM1, GRM5, DNER, Yo, ZIC4, GAD67, amphiphysin, CV2, Hu, Ri, Ma2, and recoverin. Only one sample was positive (antirecoverin IgG). The present findings suggest that serum onconeural antibody positivity is rare among patients acutely admitted for inpatient psychiatric care. The clinical implications of this finding are discussed.
Asunto(s)
Anticuerpos Antineoplásicos/sangre , Trastornos Mentales/inmunología , Enfermedad Aguda , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Análisis Químico de la Sangre , Estudios Transversales , Femenino , Hospitales Psiquiátricos , Hospitales Universitarios , Humanos , Pacientes Internos , Masculino , Trastornos Mentales/epidemiología , Trastornos Mentales/etiología , Trastornos Mentales/terapia , Persona de Mediana Edad , Síndromes Paraneoplásicos del Sistema Nervioso/epidemiología , Síndromes Paraneoplásicos del Sistema Nervioso/inmunología , Síndromes Paraneoplásicos del Sistema Nervioso/psicología , Síndromes Paraneoplásicos del Sistema Nervioso/terapia , Prevalencia , Análisis por Matrices de Proteínas , Estudios Retrospectivos , Adulto JovenRESUMEN
A 63-year-old man with symptoms of depression and sexual disinhibition was admitted to a psychiatric clinic for the elderly. Because the man's symptoms rapidly became more severe he was referred to the emergency room. There, his illness was diagnosed as paraneoplastic limbic encephalitis with positive anti-Hu antibodies; this is a paraneoplastic neurological syndrome presenting with short-term memory loss, epileptic seizures and psychiatric symptoms. For the prognosis of the illness it is essential that the syndrome is diagnosed as early as possible. Since patients sometimes present with mainly psychiatric symptoms it is important that psychiatrists are fully informed about the symptoms and are able to make an accurate diagnosis.
Asunto(s)
Anticuerpos Antineoplásicos/análisis , Encefalitis Límbica/diagnóstico , Síndromes Paraneoplásicos del Sistema Nervioso/diagnóstico , Antineoplásicos/uso terapéutico , Antipsicóticos/uso terapéutico , Autoanticuerpos/análisis , Diagnóstico Precoz , Resultado Fatal , Humanos , Encefalitis Límbica/tratamiento farmacológico , Encefalitis Límbica/inmunología , Encefalitis Límbica/psicología , Masculino , Persona de Mediana Edad , Síndromes Paraneoplásicos del Sistema Nervioso/tratamiento farmacológico , Síndromes Paraneoplásicos del Sistema Nervioso/inmunología , Síndromes Paraneoplásicos del Sistema Nervioso/psicología , PronósticoRESUMEN
INTRODUCTION: We describe the case of a young woman affected by a benign ovarian teratoma with paraneoplastic encephalitis. Several cases have already been reported, but it is the first article that focuses on details of the psychiatric symptoms of this disorder. BACKGROUND: Paraneoplastic encephalitis usually begins with a prodromal phase, followed first by prominent psychiatric symptoms or, less frequently, short-term memory loss, seizure, catatonia-like symptoms, dyskynesias and, secondly, by autonomic instability and central hypoventilation requiring intensive care. In our case and to our knowledge, for the first time in the literature, the patient was hospitalized in a psychiatric unit for a suspected manic episode with psychotic features, in association with short-term memory impairment and anxiety. It has been shown that patients suffering from paraneoplastic encephalitis associated with ovarian teratoma display antibodies for anti-N-methyl-D-aspartate (NMDA) receptors in CSF or plasma (more specifically for the NR1 subunit of the NRl/NR2 heteromers required to form a functional NMDA receptor). The NR1/NR2B heteromers are preferentially expressed in the adult hippocampus/forebrain, which are brain regions involved in the pathogenesis of various psychiatric, psychotic in particular, symptoms. Furthermore, the glutamatergic NMDA receptors are the major mediator of excitotoxicity and their dysfunction had been associated with neurologic disorders, but also with schizophrenia and, more recently, with mood disorders. CASE REPORT: This case supports the idea that the dysfunction of NMDA receptors may play a major role in psychiatric disorders, especially in psychosis and affective disorders. This article will briefly summarize the different evidences and hypotheses reported in the literature on NMDA receptors implication and will report how these receptors may serve as therapeutic targets.
Asunto(s)
Autoanticuerpos/líquido cefalorraquídeo , Neoplasias Ováricas/psicología , Síndromes Paraneoplásicos del Sistema Nervioso/diagnóstico , Síndromes Paraneoplásicos del Sistema Nervioso/psicología , Receptores de N-Metil-D-Aspartato/inmunología , Teratoma/diagnóstico , Teratoma/psicología , Trastorno Bipolar/diagnóstico , Trastorno Bipolar/inmunología , Trastorno Bipolar/psicología , Encéfalo/patología , Errores Diagnósticos , Femenino , Humanos , Imagen por Resonancia Magnética , Examen Neurológico , Neoplasias Ováricas/diagnóstico , Neoplasias Ováricas/inmunología , Síndromes Paraneoplásicos del Sistema Nervioso/inmunología , Grupo de Atención al Paciente , Teratoma/inmunología , Tomografía Computarizada por Rayos X , Adulto JovenRESUMEN
BACKGROUND: Kinsbourne syndrome or opsoclonus myoclonus syndrome (OMS) is characterized by rapid, involuntary, irregular conjugate eye movements (opsoclonus), myoclonic jerking of the limbs and trunk, ataxia, and behavioral disturbances. In general, the outcome of neurologic and behavioral symptoms is poor. Studies on quality of life (Qol) and recovery after very long-term follow-up of children with OMS are lacking. METHODS: We studied long-term cancer survival, neurologic recovery, and Qol of a consecutive series of eight patients with OMS that were treated in our center. Two cross-sectional follow-up evaluations were conducted at a 3-year interval (T1 and T2). RESULTS: In four out of eight children with OMS a neuroblastoma (NBL) was diagnosed and surgically removed completely. All children received immuno-modulatory therapy, consisting of prednisone (three children), prednisone and ACTH (four children), or prednisone, ACTH, and gammaglobulin (one child). At T1, median follow-up time was 9.5 years (range 3-14 years) after OMS onset and at T2, 11.6 years (range 6-17 years). Neurologic functioning improved in all children, reflected by a significant improvement of the mean Z-score in the motor domain of the Qol questionnaire at T2 as compared to T1. In contrast, seven children continued to have a severe developmental delay at T2. No significant difference in any of the variables was found between NBL survivors and OMS patients without NBL. CONCLUSION: Cognitive and behavioral impairments and not a motor impairment, such as ataxia, appear to be predominant at long-term in children with OMS.
Asunto(s)
Síndrome de Opsoclonía-Mioclonía/complicaciones , Síndrome de Opsoclonía-Mioclonía/psicología , Calidad de Vida , Adolescente , Hormona Adrenocorticotrópica/uso terapéutico , Niño , Preescolar , Trastornos del Conocimiento/etiología , Femenino , Estudios de Seguimiento , Humanos , Masculino , Trastornos Mentales/etiología , Síndromes Paraneoplásicos del Sistema Nervioso/fisiopatología , Síndromes Paraneoplásicos del Sistema Nervioso/psicología , Prednisona/uso terapéutico , Encuestas y Cuestionarios , gammaglobulinas/uso terapéuticoRESUMEN
Two patients, a 38-year-old man and a 32-year-old woman, were admitted to a psychiatric ward. The first patient suffered from a mood disorder, personality changes and complained of several, hitherto unexplained physical symptoms. Finally the patient was diagnosed with paraneoplastic cerebellar degeneration associated with Hodgkin's disease. The second patient presented with psychosis and panic disorders, but the condition was later found to be caused by paraneoplastic limbic encephalitis due to ovarian teratomas. These cases illustrate that patients with paraneoplastic neurological syndromes may present with psychiatric symptoms which can hamper an early diagnosis.
Asunto(s)
Enfermedad de Hodgkin/psicología , Neoplasias Ováricas/psicología , Síndromes Paraneoplásicos del Sistema Nervioso/psicología , Teratoma/psicología , Adulto , Diagnóstico Diferencial , Femenino , Enfermedad de Hodgkin/complicaciones , Enfermedad de Hodgkin/diagnóstico , Humanos , Masculino , Neoplasias Ováricas/complicaciones , Neoplasias Ováricas/diagnóstico , Síndromes Paraneoplásicos del Sistema Nervioso/complicaciones , Síndromes Paraneoplásicos del Sistema Nervioso/diagnóstico , Teratoma/complicaciones , Teratoma/diagnósticoRESUMEN
Opsoclonus-myoclonus ataxia syndrome is a paraneoplastic syndrome of cerebellar damage associated with neuroblastoma. The authors assessed psychiatric symptoms of opsoclonus-myoclonus ataxia syndrome in 17 children, who were 16 months to 12(1/2) years of age. Psychiatric symptoms examined included disruptive behavior, affective dysregulation, irritability, impulsivity, cognitive impairment, and poor attention.
Asunto(s)
Ataxia Cerebelosa/diagnóstico , Trastornos de la Conducta Infantil/diagnóstico , Trastornos del Humor/diagnóstico , Síndromes Paraneoplásicos del Sistema Nervioso/diagnóstico , Ataxia Cerebelosa/psicología , Niño , Trastornos de la Conducta Infantil/psicología , Preescolar , Trastornos del Conocimiento/diagnóstico , Trastornos del Conocimiento/psicología , Discapacidades del Desarrollo/diagnóstico , Discapacidades del Desarrollo/psicología , Femenino , Estudios de Seguimiento , Ganglioneuroblastoma/cirugía , Humanos , Lactante , Masculino , Trastornos del Humor/psicología , Neuroblastoma/cirugía , Examen Neurológico , Pruebas Neuropsicológicas , Síndromes Paraneoplásicos del Sistema Nervioso/psicología , Complicaciones Posoperatorias/diagnóstico , Complicaciones Posoperatorias/psicologíaRESUMEN
OBJECTIVES: Parents of children with opsoclonus-myoclonus syndrome (OMS) frequently describe poor sleep and rage attacks. We hypothesized that these manifestations are related and could result from underlying monoaminergic dysfunction. STUDY DESIGN: We clinically characterized the sleep and behavioral characteristics of 51 young children with OMS; 19 of those with the most disruptive sleep patterns were treated with trazodone, a soporific serotonergic agent. RESULTS: Sleep disturbances, including prolonged sleep latency, fragmented sleep, reduced quantity of sleep, snoring, and non-restorative sleep, were reported in 32 children, and frequent rage attacks were reported in 25. In 59% of the poor sleepers, parents felt that the problem was severe enough to warrant treatment. Children sleeping <10 hours/night had a higher rage frequency than those who slept more. Of the children who required trazodone, 84% were receiving corticosteroids or adrenocorticotropic hormone (corticotrophin), compared with 37% in the subgroup with normal sleep. Trazodone (3.0 +/- 0.4 mg/kg/day) improved sleep and behavior in 95% of the children, significantly increasing total sleep time by 72%, decreasing the number of awakenings by 76%, and reducing rage attacks by 33%. CONCLUSIONS: Children with OMS exhibited multiple types of sleep disturbances, which contributed to rage attacks. Trazodone was effective in improving sleep and decreasing rage attacks and was well tolerated, even in toddlers.
Asunto(s)
Síntomas Afectivos/tratamiento farmacológico , Síndromes Paraneoplásicos del Sistema Nervioso/psicología , Furor , Inhibidores Selectivos de la Recaptación de Serotonina/uso terapéutico , Trastornos del Sueño-Vigilia/tratamiento farmacológico , Trazodona/uso terapéutico , Adolescente , Síntomas Afectivos/etiología , Niño , Preescolar , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Lactante , Masculino , Estudios Retrospectivos , Trastornos del Sueño-Vigilia/etiología , Trazodona/administración & dosificación , Resultado del TratamientoRESUMEN
A 65-year-old male patient developed truncal ataxia, opsoclonus and myoclonus. In the serum anti-Ri antibodies were found, which led to the detection of a small adenocarcinoma of the breast. Other prominent clinical features were an excessive startle response and behavioral disorders, such as anxiety and impatience. These features suggest an immune response against both Nova-1 and Nova-2 antigens throughout the central nervous system.
Asunto(s)
Anticuerpos Antineoplásicos/sangre , Antígenos de Neoplasias/inmunología , Neoplasias de la Mama Masculina/sangre , Proteínas del Tejido Nervioso , Síndromes Paraneoplásicos del Sistema Nervioso/sangre , Proteínas de Unión al ARN , Anciano , Anticuerpos Antineoplásicos/biosíntesis , Neoplasias de la Mama Masculina/diagnóstico , Neoplasias de la Mama Masculina/psicología , Humanos , Masculino , Antígeno Ventral Neuro-Oncológico , Síndromes Paraneoplásicos del Sistema Nervioso/diagnóstico , Síndromes Paraneoplásicos del Sistema Nervioso/psicologíaAsunto(s)
Encefalitis Límbica/diagnóstico , Síndromes Paraneoplásicos del Sistema Nervioso/diagnóstico , Enfermedades del Sistema Nervioso Periférico/diagnóstico , Trastornos Psicóticos/diagnóstico , Humanos , Encefalitis Límbica/psicología , Masculino , Persona de Mediana Edad , Síndromes Paraneoplásicos del Sistema Nervioso/psicología , Enfermedades del Sistema Nervioso Periférico/psicología , Trastornos Psicóticos/psicología , Esquizofrenia Paranoide/diagnóstico , Esquizofrenia Paranoide/psicología , Negativa del Paciente al TratamientoRESUMEN
Paraneoplastic limbic encephalitis (PLE) is a rare disorder characterized by personality changes, irritability, depression, seizures, memory loss and sometimes dementia. The diagnosis is difficult because clinical markers are often lacking, and symptoms usually precede the diagnosis of cancer or mimic other complications. The frequency of antineuronal antibodies in patients with PLE has not been investigated. We examined the neurological symptoms and the causal tumours in 50 patients with PLE to determine the utility of paraneoplastic antibodies and other tests. The diagnosis of PLE required neuropathological examination or the presence of the four following criteria: (i) a compatible clinical picture; (ii) an interval of <4 years between the development of neurological symptoms and tumour diagnosis; (iii) exclusion of other neuro-oncological complications; and (iv) at least one of the following: CSF with inflammatory changes but negative cytology; MRI demonstrating temporal lobe abnormalities; EEG showing epileptic activity in the temporal lobes. Of 1047 patients with neurological symptoms, whose sera or CSF were examined for paraneoplastic antibodies, 79 had the presumptive diagnosis of limbic encephalitis, dementia, cognitive dysfunction, or confusion. Fifty of these patients fulfilled our criteria for PLE. Pathological confirmation was obtained in 12 patients. The commonly associated neoplasms were of the lung (50%), testis (20%) and breast (8%). Neurological symptoms preceded the cancer diagnosis in 60% of patients (by a median of 3.5 months). Twenty-five of 44 (57%) patients with MRI studies had signal abnormalities in the limbic system. Thirty (60%) patients had antineuronal antibodies (18 anti-Hu, 10 anti-Ta, 2 anti-Ma), and 20 were antibody-negative or had uncharacterized antibodies (n = 4). The combination of symptoms, MRI findings and paraneoplastic antibodies established the diagnosis of PLE in 78% of the patients. Patients with anti-Hu antibodies usually had small-cell lung cancer (94%), multifocal neurological symptoms (78%) and a poor neurological outcome. Patients with anti-Ta (also called anti-Ma2) antibodies were young men with testicular tumours (100%), frequent hypothalamic involvement (70%) and a poor neurological outcome. In the group of patients without anti-Hu or anti-Ta antibodies, the tumour distribution was diverse, with cancer of the lung the most common (36%); 57% had positive MRI. Fifteen of 34 (44%) patients with a median follow-up of 8 months showed neurological improvement. Treatment of the tumour appeared to have more effect on the neurological outcome than the use of immune modulation. Improvement was observed in 38% of anti-Hu patients, 30% of anti-Ta patients and 64% of patients without these antibodies.